http://www.theage.com.au/news/business/costello-and-kennett-in-harmony-at-last/2006/09/27/1159337223066.html?page=fullpage
"Partner wanted
FOUR weeks ago Alchemia shareholders were gutted — as was the share price — when the company's US marketing partner Abraxis got cold feet before the joint research agreement on the generic drug heparin was completed. The shares slumped from 83¢ to 57.5¢.
CEO Tracie Ramsdale has been peddling hard since then, and yesterday reported that the research agreement would be terminated and Alchemia would return the heparin in its custody and repay a $1.25 million loan to Abraxis.
What's more, Alchemia would go it alone seeking US approval to market heparin and would also start looking for another marketing partner. Dow's successful production of heparin this year meant the project was at a low-risk stage, she said.
Investors appeared to agree, although they were still not quite as confident as they were a month ago. The shares surged 5.5¢ to 68.5¢ yesterday, but they have still not recovered half the loss suffered a month ago."
- Forums
- ASX - By Stock
- re:partnership officially broken
http://www.theage.com.au/news/business/costello-and-kennett-in-ha...
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online